Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Grifols Stock Declines After Brookfield Drops Buyout Offer
Grifols Stock Declines After Brookfield Drops Buyout Offer Zacks Investment Research - Thu Nov 28, 10:10AM CST

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
GRFS : 7.51 (-2.72%)
SPRO : 0.9551 (-4.30%)
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% Zacks Investment Research - Wed Nov 20, 9:38AM CST

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 1.0900 (-0.91%)
CSTL : 27.53 (+1.62%)
GRFS : 7.51 (-2.72%)
SPRO : 0.9551 (-4.30%)
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain PR Newswire - Tue May 23, 2023

/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...

GRFS : 7.51 (-2.72%)
Why Shares of Grifols Were Up Tuesday Motley Fool - Tue May 9, 2023

The company gave first-quarter numbers.

GRFS : 7.51 (-2.72%)
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 PR Newswire - Tue Apr 18, 2023

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

GRF : 10.30 (+0.03%)
GRFS : 7.51 (-2.72%)
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease PR Newswire - Mon Mar 6, 2023

/PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research,...

GRFS : 7.51 (-2.72%)
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson PR Newswire - Mon Oct 3, 2022

Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is...

GRF : 10.30 (+0.03%)
GRFS : 7.51 (-2.72%)
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada Newswire.ca - Wed Sep 7, 2022

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...

GRF : 10.30 (+0.03%)
GRFS : 7.51 (-2.72%)
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada PR Newswire - Wed Sep 7, 2022

The country, with an increasing immunoglobulin (Ig) usage rate, currently imports about 85% of its Ig demand for patients in Canada who rely on this lifesaving...

GRF : 10.30 (+0.03%)
GRFS : 7.51 (-2.72%)
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond Motley Fool - Thu May 26, 2022

These three healthcare stocks should hold their value for years.

BAYRY : 4.9100 (-0.41%)
TAK : 13.10 (+0.69%)
GRFS : 7.51 (-2.72%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot